TUESDAY, Nov. 14, 2017 -- Offering both the promise of better patient compliance with health care, but also fears of a medical "Big Brother," a newly approved "digital pill" allows physicians to track whether or not it's been ingested by patients.
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, as an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder.
MONDAY, Oct. 23, 2017 -- Certain factors related to pregnancy and delivery may affect a woman's risk of having postpartum depression, a new study suggests.
The study showed that giving birth in the winter or the spring was linked to a lower risk of developing postpartum depression, as was having a baby at full-term. Using anesthesia during delivery also appears to lower the risk of postpartum depression.